RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial

• DOI: 10.1093/annonc/mdx417
• Publication Date: 2017-08-04T11:09:08Z
• Authors: N. Normanno; R. Esposito Abate; M. Lambiase; L. Forgione; C. Cardone; A. Iannaccone; A. Sacco; A.M. Rachiglio; E. Martinelli; D. Rizzi; S. Pisconti; M. Biglietto; R. Bordonaro; T. Troiani; T.P. Latiano; F. Giuliani; S. Leo; A. Rinaldi; E. Maiello; F. Ciardiello
• Keywords: FOLFIRI; Liquid biopsy; Concordance

Liquid biopsy is an alternative to tissue for RAS testing in metastatic colorectal carcinoma (mCRC) patients. Little information available on the predictive role of liquid patients treated with first-line anti-EGFR monoclonal antibody-based therapy.In CAPRI-GOIM trial, 340 KRAS exon-2 wild-type mCRC received cetuximab plus FOLFIRI. Tumor samples were retrospectively assessed by next generation sequencing (NGS). Baseline plasma analyzed and NRAS mutations using beads, emulsion, amplification, magnetics digital PCR (BEAMing). Discordant cases solved droplet (ddPCR) or deep-sequencing.A subgroup 92 both NGS data tumor baseline included this study. Both analysis BEAMing identified 33/92 (35.9%). However, 10 mutant wild-type, additional mutant, resulting a concordance rate 78.3%. Analysis ddPCR detected 2/10 In contrast, all cases, deep-sequencing confirmed presence at allelic frequencies ranging between 0.15% 1.15%. The median progression-free survival according (7.9 versus 12.6 months; P = 0.004) (7.8 13.8 moths; < 0.001) comparable. Similar findings observed overall based (22.1 35.8 0.016) (19.9 0.013) analysis.This study indicates that results similar outcome when compared receiving antibodies.